Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Telisotuzumab vedotin |
Synonyms | |
Therapy Description |
Emrelis (telisotuzumab vedotin) is an antibody-drug conjugate comprising a MET-targeted antibody linked to MMAE, which delivers the cytotoxic agent to MET-expressing tumor cells, resulting in cell death (PMID: 27573171, PMID: 32127466). Emrelis (telisotuzumab vedotin) is FDA-approved for use in patients with non-squamous non-small cell lung cancer with high Met overexpression (FDA.gov). |